Latest news with #ICARS
Time of India
11 hours ago
- Health
- Time of India
Bengaluru C-CAMP, ICARS launch AMR innovation challenge
Representative Image BENGALURU: The Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, in partnership with the International Centre for Antimicrobial Resistance Solutions (ICARS), has launched the One Health AMR Challenge 2025. This initiative aims to support technologies addressing antimicrobial resistance (AMR) across human, animal, and environmental health. 'The initiative, anchored under the India AMR Innovation Hub (IAIH) at C-CAMP, will identify up to 12 mid to late-stage innovations with Technology Readiness Levels 6–9. Selected technologies will receive financial support of Rs 40 lakh to Rs 2 crore, along with regulatory, IP, legal, manufacturing, and market-readiness assistance,' C-CAMP said on Monday. Applications opened on July 3 and will close on August 3. Focus areas include the detection of respiratory infections in humans, zoonotic diagnostics, reducing antibiotic use in livestock, removing pharmaceutical residues from effluents, and timely detection of bovine mastitis. You Can Also Check: Bengaluru AQI | Weather in Bengaluru | Bank Holidays in Bengaluru | Public Holidays in Bengaluru C-CAMP CEO Dr Taslimarif Saiyed said the challenge is aligned with India's upcoming National Action Plan 2.0 and aims for the rapid scale-up of near-market solutions. ICARS and C-CAMP also plan to mobilise further funding to expand the initiative's reach.
Metro
26-04-2025
- Health
- Metro
My child didn't want to put his shoes on
The school's number flashed up on my phone. I paused, took a breath, and answered. 'Good afternoon, letting you know that your son has been defiant today and placed in isolation because he didn't want to put his shoes on after soft play. 'During this time, he soiled himself and smeared it everywhere. We wheeled him in a trolley to the showers and scrubbed him down. He was very upset and angry and had to be restrained by at least four members of staff.' As the words trickled down the phone, I shook, sickened. My body knew before my mind caught up — my child had been violated, not supported. My son – who was in the latter years of primary school – wasn't 'defiant', he was overwhelmed. Dysregulated. Frightened. He needed co-regulation, not confrontation. He needed someone to sit beside him, not pin him down. This incident — avoidable and unnecessary — was just one in a string of failures. But it was the one that broke something in me. My son was born with Down's syndrome, then diagnosed autistic several years later. His speech was unique. Compulsive, with extreme sensory needs and avoidance of everyday tasks, he found the busy school environment with all the daily transitions extremely difficult. In a class with 10 other children – all with profound multiple learning disabilities – he found ways of masking and said 'yes' to a lot of things he didn't understand, so people would leave him alone. On top of that, he would vomit daily on the school minibus, so I would be called to pick him up. This is regardless of me explaining it wasn't a bug, but anxiety. The stress eventually caused him to lose all his hair. He was soon labelled as naughty. Children were regularly grabbed, held down, and isolated for behaviours that were actually cries for help We asked for support. Instead, we were blamed. We were told his behaviours were our fault — that we were too soft, too emotional, too much. I became 'that Mum'. We'd regularly be told, 'He needs to learn' and 'Your standards are too high', 'Stop worrying!' or 'No one else has a problem with it'. Then the incident happened when I was called about my son being restrained. On that occasion, isolation areas were lockable and padded sections separate to class, but children could hear others' distress through the walls. I had impressed on teachers many times how important it was never to leave him alone because of his anxiety, as it triggered his incontinence. He would have been naked, confused, and utterly terrified. He wasn't maliciously violent, he just hadn't put his shoes on. On other occasions, my boy would return home with unexplained hand-shaped bruises and scratches, but the school diary would simply state 'he has had a good day, all fine'. When challenged, teachers would say 'another child did it'. I have since learnt that at that school, restraint was covertly routine. Children were regularly grabbed, held down, and isolated for behaviours that were actually cries for help. ICARS supports children who have suffered restraint and seclusion abuse in schools. For more information, visit their website here. The final straw came when I witnessed a child being carried kicking and shrieking up the corridor in the equivalent of a gigantic hold-all. The staff recoiled. I wasn't meant to see that. It was dehumanising. It was treated as normal. I raised concerns, but was silenced each time. I look back now with regret. His fear of school was palpable, but over time I was made to doubt my own sanity. The guilt of sending him to this unsafe place engulfed me. So we removed him and were left to fend for ourselves, effectively off-rolled under the guise of an 'elective' choice for home education. Forced out. The school would not admit they couldn't meet his needs. It all had a nuclear impact. The whole experience destroyed his curiosity of learning new things. Only recently, through tears, he said: 'School cruel'. The fact it took years for him to say this speaks volumes and shows the depth of the trauma. A sensitive, funny, and deep-thinking young person, but his complexity was interpreted as being deliberately disobedient. Viewing recent footage of a 12-year-old child being restrained at a special school brings back the sheer horror we faced. Five members of staff were involved while he was held face-down on the floor in a prone restraint. Another child, another family. The truth is this is not an exception, it seems to be a regular practice and happens not only in schools both mainstream and specialist, but also care homes and hospitals. Now, as a young disabled adult, my son struggles — being manhandled and misunderstood has left scars that are still trying to heal. He has PTSD. We're fighting to secure care support and nurturing education, while public services are stretched thinner than pizza dough. The future feels like a cliff edge. A fundamental shift is needed in how we care for vulnerable, disabled, and neurodivergent people. Instead of convenience and compliance, the default must be connection. Trust, not threats. The goal is dignity and respect, not long-lasting damage. More Trending Every one of us has a duty to speak up. To challenge abuse. To act when our gut tells us something is wrong. Because if we stay silent, we become complicit. My son deserved safety. He deserved compassion. He deserved to be seen. Every child does. This article was originally published April 16, 2025 Do you have a story you'd like to share? Get in touch by emailing Share your views in the comments below. MORE: Dad, 24, took his own life after being arrested over newborn son's death MORE: I went to give my ex head – then I vomited MORE: Nadia Almada: I almost certainly wouldn't win Big Brother now as a trans woman
Yahoo
16-04-2025
- Business
- Yahoo
Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG
GLM101 is the first disease-modifying therapeutic in development to treat PMM2-CDG, the most common congenital disorder of glycosylation Data from the ongoing Phase 2 open-label study of GLM101 provide clinical proof of concept, showing improvement in ataxia, a key burden of disease in PMM2-CDG Funding will support advancement of GLM101 into a randomized, placebo-controlled Phase 2b safety and efficacy study SAN CARLOS, Calif., April 16, 2025--(BUSINESS WIRE)--Glycomine, Inc., a biotechnology company focused on developing transformative new therapies for orphan diseases, today announced a $115 million Series C financing to advance its lead candidate, GLM101, into a Phase 2b clinical trial. The financing was led by CTI Life Sciences Fund, funds managed by abrdn Inc., and Advent Life Sciences, alongside continued investment from existing investors, Novo Holdings, Sanofi Ventures, Abingworth, RiverVest Venture Partners, Sanderling Ventures, Chiesi Ventures, Remiges Ventures, and Asahi Kasei Ventures. "We are excited to partner with our new investors who have strong track records in rare diseases and for the continued support from our existing investors," said Steve Axon, Glycomine's CEO. "This financing will enable us to advance GLM101 into a randomized, placebo-controlled trial later this year—an important step toward bringing the first disease-modifying therapeutic to patients with PMM2-CDG." GLM101, a first-in-class mannose-1-phosphate replacement therapy, is in development for phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG), a rare and life-threatening genetic disorder with no approved treatments. Glycomine has enrolled more than 20 patients across Europe and the U.S. in its ongoing Phase 2 study and recently initiated dosing in pediatric patients. Data from Glycomine's ongoing Phase 2 open-label study have demonstrated promising improvements in ataxia, a hallmark debilitating manifestation of PMM2-CDG. Among nine adult and adolescent patients, treatment with GLM101 led to an average 11.9-point improvement on the ICARS (International Cooperative Ataxia Rating Scale) over 24 weeks. "We are impressed by the therapeutic approach and strong progress of the Glycomine team," said Youssef Bennani, Ph.D., Managing Partner with CTI Ventures. "We are excited to be part of such a strong investor syndicate and look forward to the potential of making a positive impact in the lives of patients with PMM2-CDG." Dominic Schmidt, Ph.D., General Partner with Advent Life Sciences added, "We are highly encouraged by the clinical signal observed in the ongoing Phase 2 study. Most notably, the data show strong potential for clinically meaningful improvement in ataxia, a key driver of disease burden for PMM2-CDG patients." In connection with the financing, Drs. Bennani and Schmidt have been appointed to Glycomine's Board of Directors. About PMM2-CDG Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), previously known as CDG-1a, is the most prevalent congenital disease of glycosylation. PMM2-CDG is caused by a genetic mutation in phosphomannomutase 2 (PMM2), which results in the protein having reduced activity. PMM2 is an enzyme that converts mannose-6-phosphate to mannose-1-phosphate, which is required to insert the mannose sugar building block into developing glycans that are crucial for proper protein structure and function. The deficiency of mannose-1-phosphate disrupts the process of N-glycosylation and causes a wide array of clinical symptoms and, in many cases, can be life-threatening. About Glycomine, Inc. Glycomine is a clinical-stage biotechnology company that is advancing treatments for serious rare diseases for which no other therapeutic options exist. The Company's lead investigational drug candidate GLM101 is a mannose-1-phosphate replacement therapy in development to treat PMM2-CDG. GLM101 is designed to deliver mannose-1-phosphate into cells and thereby bypass disease-causing PMM2 mutations to restore pathway function. GLM101 has received Orphan Drug Designation in the U.S. and E.U. and Rare Pediatric Disease Designation and Fast Track Designation in the U.S. The company is based in San Carlos, California, and supported by leading international life sciences investors. For more info visit View source version on Contacts Corporate Contact: Peter McWilliams, Ph.D., info@ Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@ Sign in to access your portfolio
